Cantor Fitzgerald’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
Other funds holding MLTX
Cantor Fitzgerald's MLTX Position: Q3 2026 in Review
Cantor Fitzgerald opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2026: 35,000 shares worth $410K. The stake represents ﹤0.01% of the portfolio and ranks #498 among its holdings. This is a return to the name: Cantor Fitzgerald previously reported a position in MLTX as recently as Q1 2025.
Cantor Fitzgerald first reported a position in MLTX in Q1 2025 and has held it in 2 quarters since. The position peaked at $977K in Q1 2025. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.
- Cantor Fitzgerald held 35,000 shares of MoonLake Immunotherapeutics worth $410K as of Q3 2026.
- MoonLake Immunotherapeutics was a new Cantor Fitzgerald position in Q3 2026.
- MoonLake Immunotherapeutics made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q3 2026, its #498 holding.
- Cantor Fitzgerald first reported a position in MoonLake Immunotherapeutics in Q1 2025 and has held it in 2 quarters since.
- Cantor Fitzgerald's MoonLake Immunotherapeutics position peaked at $977K in Q1 2025.
- 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.
Based on Cantor Fitzgerald's 13F filing for Q3 2026, filed 16 Nov 2026.